In the unlikely event you haven't seen this over at the WSJ Health Blog today , we felt the need to post this here as well. Bio-Rad has ...

One of the simplest metrics we have to measure interest in a company or industry is just how jammed the rooms are at the JP Morgan conferenc...

Steve Nissen's latest star turn , advising doctors everywhere to stop using Vytorin until there is better evidence it improves health ou...

In most venture circles, talk around forming an international strategy generally leads to VCs staging fact-finding missions to China and Ind...

It’s the headline lay media outlets love to report: “High-Cost Cholesterol Drug Combo Shows No Benefit Over Lower-Cost Generic Statin.” From...

You know what he's going to say ... Remind you of this?

Look both ways before you cross The Street Roger Longman's earlier post about biotech hype got us thinking about a few conversations w...

The dismal failure of Pfizer/Nektar’s Exubera loudly called into question whether inhaled mealtime insulin was commercially viable at all. ...

As he strode to the podium in during last week’s JP Morgan investor conference in San Francisco, Stryker Corp. CEO Steve MacMillan was all s...

Active surveillance and data mining are scary, right? It is common wisdom that these tools in the hands of academics, health plans and regul...